IL31413A - Pharmaceutical compositions containing ethybenzatropine,dihydroergocristine and mesoridazine - Google Patents

Pharmaceutical compositions containing ethybenzatropine,dihydroergocristine and mesoridazine

Info

Publication number
IL31413A
IL31413A IL31413A IL3141369A IL31413A IL 31413 A IL31413 A IL 31413A IL 31413 A IL31413 A IL 31413A IL 3141369 A IL3141369 A IL 3141369A IL 31413 A IL31413 A IL 31413A
Authority
IL
Israel
Prior art keywords
constituent
dihydroergocristine
pharmaceutical composition
mesoridazine
composition according
Prior art date
Application number
IL31413A
Other languages
English (en)
Other versions
IL31413A0 (en
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of IL31413A0 publication Critical patent/IL31413A0/xx
Publication of IL31413A publication Critical patent/IL31413A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL31413A 1968-01-16 1969-01-14 Pharmaceutical compositions containing ethybenzatropine,dihydroergocristine and mesoridazine IL31413A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH64768 1968-01-16

Publications (2)

Publication Number Publication Date
IL31413A0 IL31413A0 (en) 1969-03-27
IL31413A true IL31413A (en) 1972-04-27

Family

ID=4191874

Family Applications (1)

Application Number Title Priority Date Filing Date
IL31413A IL31413A (en) 1968-01-16 1969-01-14 Pharmaceutical compositions containing ethybenzatropine,dihydroergocristine and mesoridazine

Country Status (11)

Country Link
US (1) US3629471A (pt)
AT (1) AT305490B (pt)
BE (1) BE726861A (pt)
CA (1) CA921827A (pt)
DE (1) DE1901496A1 (pt)
FR (1) FR8107M (pt)
GB (1) GB1242315A (pt)
IE (1) IE32617B1 (pt)
IL (1) IL31413A (pt)
NL (2) NL6818657A (pt)
SE (1) SE361598B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966923A (en) * 1972-06-05 1976-06-29 Pierre Fabre S.A. Medicaments intended for the prevention and treatment of ischemic disturbances

Also Published As

Publication number Publication date
GB1242315A (en) 1971-08-11
US3629471A (en) 1971-12-21
AT305490B (de) 1973-02-26
IL31413A0 (en) 1969-03-27
SE361598B (pt) 1973-11-12
FR8107M (pt) 1970-07-27
NL136837C (pt)
BE726861A (pt) 1969-07-14
NL6818657A (pt) 1969-07-18
IE32617B1 (en) 1973-10-03
DE1901496A1 (de) 1969-08-28
CA921827A (en) 1973-02-27
IE32617L (en) 1969-07-16

Similar Documents

Publication Publication Date Title
US4273774A (en) Central nervous system compositions and method
US5750537A (en) Use of 5HT3 antagonist to treat impotence
AU579028B2 (en) Anticonvulsant compositions and method
CA1277916C (en) Pharmaceutical preparations having an antihypertensive and cardio-protective effect
IL31413A (en) Pharmaceutical compositions containing ethybenzatropine,dihydroergocristine and mesoridazine
US3852453A (en) Method of enhancing vincamine compositions
JPH0361644B2 (pt)
DE3525390C2 (pt)
US3911136A (en) 1-(O-METHOXY-PHENOXY)-3-ISOPROPYL-AMINO-PROPANE-2-OL HCl and nitroglycerine coronary insufficiency composition
KR100352898B1 (ko) 새로운3-벤조일-3,7-디아자바이사이클로[3,3,1]노난-화합물을함유하는약제
US3733423A (en) Hydrogenated ergot alkaloid compositions and methods of using same
Meyer Oral Administration of Co60 Vitamin B12 in Pernicious Anemia.
GB1600639A (en) Medicament preparation having resorption properties and method of producing the same
KR890014109A (ko) 의약제
CA1139670A (en) Process and composition for reducing blood pressure in animals
US3795736A (en) 5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-(1) benzopyrano(3,4-d)pyridine as an analgesic agent
US3108041A (en) Antitussive compositions
van Rooyen, JM & Offermeier Peripheral dopaminergic receptors-physiological and pharmaceutical aspects of therapeutic importance
Nies et al. Recent concepts in the clinical pharmacology of anithypertensive drugs
US3914425A (en) Antitussive codeine composition
JPH03502802A (ja) 抗嘔吐性エルゴリン誘導体
CA1109796A (en) Process for the production of novel antidiarrheal agents
US3987173A (en) Pharmaceutical preparations comprising vincamine alkaloids and dihydroergocristine
US3567828A (en) Organic compounds
US3800041A (en) Analgesic compositions and methods